Your session is about to expire
← Back to Search
Cirmtuzumab + Ibrutinib for Lymphoma
Study Summary
This trial is testing a new drug to see if it is safe and effective when given with another drug to patients with B-cell lymphoid malignancies (cancer).
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have signs of GVHD after a stem cell transplant.I finished all my cancer treatments at least a week ago.I can take care of myself and am up and about more than half of my waking hours.My cancer can be seen and measured on scans.I do not have an ongoing infection when starting the study treatment.I have not had major surgery in the last 4 weeks.I have a known brain or spinal cord tumor.I have a stomach or intestine condition that could affect how medicine is absorbed.I need treatment because my symptoms or cancer spread are getting worse.My lymphoma has changed into a more aggressive form.I haven't taken strong medication that affects liver enzymes in the last week.My blood, liver, kidney, and clotting tests are normal.I have had a solid organ transplant.I haven't had anti-ROR1 therapy in the last 3 months.I cannot use ibrutinib due to a bleeding disorder.I haven't had major heart problems in the last 3 months.I am 18 years old or older.I do not have another cancer that could impact my safety or the study's results.My doctor thinks ibrutinib is a suitable treatment for me.My medical records show I have CLL/SLL, MCL, or MZL.
- Group 1: Part 3 - Arm B
- Group 2: Part 3 - Arm A
- Group 3: Part 1
- Group 4: Part 2
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any vacancies available for participation in this experiment?
"Absolutely, clinicaltrials.gov has explicit information that indicates this medical trial is actively enrolling patients. The project was initially posted on March 1st 2018 and the most recent update came on June 16th 2022. 138 individuals from 9 different sites are required for successful completion of the study."
How many participants are involved in this trial?
"Affirmative. According to information hosted on clinicaltrials.gov, this experiment is actively seeking applicants and was initially posted on March 1st 2018; the listing has since been updated most recently on June 16th 2022. A total of 138 participants are requested from 9 different medical sites."
In which geographical areas is this experiment accessible?
"The trial is being conducted at a variety of sites, including the UCSD Moores Cancer Center in La Jolla and Sanford Stem Cell Clinical Center at UCSD in New Hyde Park. Additionally, Northwell Health in New Haven as well as other medical hubs are also hosting this clinical study."
What findings have been reported in studies conducted with Cirmtuzumab and ibrutinib?
"Cirmtuzumab plus ibrutinib was initially investigated in 2011 at the NIH Clinical Center, 9000 Rockville Pike. A total of 97 trials have been completed while 155 are still ongoing; many out of La Jolla and New york City."
What are the key goals of this exploration?
"This medical trial sets out to measure the Complete Response Rate over 72 weeks following recruitment of the final subject. Secondary objectives involve changes in ROR1 cell surface expression and receptor occupancy, treatment-emergent adverse events (TEAEs) as assessed by CTCAE v4.03, and Time to Response (TTR)."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger